To include your compound in the COVID-19 Resource Center, submit it here.

Cometriq cabozantinib: Phase III data

Based on the data, Exelixis will reduce headcount by 70%, or about 160, to about 70. The company declined to disclose how much it expects to save from the headcount reduction, but said it expects a restructuring charge of $6-$8 million. Exelixis had

Read the full 433 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers